SP1 and cancer: The conclusions obtained from the data on M4N suggest that, while a combination treatment of an HIF-1 inhibitor with an SP1 inhibitor might improve the anticancer efficacy of the drugs to some extent without curing most cancer patients, a combination treatment of HIF-1 and SP1 inhibitors with a third appropriately selected anticancer drug might significantly improve the anticancer activity of the third drug.